Please contact us with any questions or if you'd like to explore your legal rights
Name 
Email Address 
Phone 
Message 

Serevent

The Law Firm of Motley Rice LLC Legal services for people harmed by pharmaceutical products such as Bextra
When the FDA approved a new drug called Serevent (salmeterol xinafoate) for the treatment of asthma in 1994, they were unaware of the problems to come. Serevent, also manufactured by GlaxoSmithKline, had its FDA-approved use extended to include treatment of chronic obstructive pulmonary disease. Presumably, if used daily, Serevent controls the symptoms of asthma and is considered a long-acting bronchodilator. While Serevent enjoys great popularity with asthma victims, many users remain unaware that a recent study showed that users of Serevent are three times more likely to die from asthma-related deaths as are users of other asthma medications.

Serevent Safety Questioned

The Salmeterol Multi-Center Asthma Research Trial (SMART) study began in 1996 to assess the safety of Serevent and its relationship to serious asthma-related health problems and was halted on January 23, 2003 when the Food & Drug Administration (FDA) announced that Serevent may be associated with an increased risk of asthma-related deaths. The study also suggested that there may be greater risks associated with Advair and Serevent in African-American patients.

The FDA asked GSK, the manufacturer of both Advair and Serevent, to revise the products to carry the strongest Food and Drug Administration label warning due to the results of a further study, which revealed the serious side effects associated with the use of Advair and Serevent. The SMART study reported that more people using Advair or Serevent died than those taking a placebo drug.
The Law Firm of Motley Rice LLC Legal services for people harmed by pharmaceutical products such as Bextra Please contact us with any questions or if you'd like to explore your legal rights.